Beta Cell Imaging in T1D Patients With a Different Glycemic Control

NCT03785275 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2022-02-14

No results posted yet for this study

Summary

The primary aim of this study is to measure (residual) beta cell mass in type 1 diabetes (T1D) patients with stable near-normal and unstable glucose control using PET/CT imaging, to improve the understanding of the relation between beta cell mass and glycemic control in T1D.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

RADIATION

gallium-68-exendin PET/CT

PET/CT scan after injection with gallium-68-exendin

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-06
Primary Completion
2020-11-09
Completion
2020-11-09

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03785275 on ClinicalTrials.gov